Sage Therapeutics' GAAP loss for 3 months of 2022 was $122.055 million, up 27.5% from $95.764 million in the prior year. Revenue decreased 0.1% to $1,582 million from $1,583 million a year earlier.
Sage Therapeutics' GAAP loss for 3 months of 2022 was $122.055 million, up 27.5% from $95.764 million in the prior year. Revenue decreased 0.1% to $1,582 million from $1,583 million a year earlier. 
investor.sagerx.com
English (US) 